Abstract
This research letter discusses the association between label restrictions by the US Food and Drug Administration on first-line immunotherapy for advanced bladder cancer and subsequent changes in practice.
Publication types
-
Research Support, N.I.H., Extramural
MeSH terms
-
Aged
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Antineoplastic Agents / therapeutic use*
-
Cisplatin / therapeutic use
-
Drug Labeling / legislation & jurisprudence*
-
Drug Therapy / trends*
-
Female
-
Government Regulation
-
Humans
-
Immunotherapy / trends*
-
Logistic Models
-
Male
-
Product Surveillance, Postmarketing
-
Programmed Cell Death 1 Receptor / antagonists & inhibitors*
-
United States
-
United States Food and Drug Administration
-
Urinary Bladder Neoplasms / drug therapy*
-
Urinary Bladder Neoplasms / therapy
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents
-
Programmed Cell Death 1 Receptor
-
atezolizumab
-
pembrolizumab
-
Cisplatin